SynthesisBMC psychiatry2025
Predicting the treatment outcomes of major depressive disorder interventions with baseline resting-state functional connectivity: a meta-analysis.
Synthesis in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Research trends and knowledge mapping of transcranial direct current stimulation in depression: a bibliometric study based on web of science, Scopus, and PubMed (2000-2025).Frontiers in psychiatry · 2026Pooled it
- Zinc Ameliorates LPS-Induced Depressive-Like Behaviors Via Modulating Microglial Polarization.Biological trace element research · 2026Article
- Artificial Intelligence in Drug Discovery and Development: Raising Quality per Decision.Pharmacopsychiatry · 2026Review
- Virtual sailing exercise to improve major depressive disorder: A pilot clinical trial protocol.Contemporary clinical trials communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCurrent interventions for major depressive disorder (MDD) demonstrate limited and heterogeneous efficacy, highlighting the need for improving the precision of treatment. Although findings have been mixed, resting-state functional connectivity (rsFC) at baseline shows promise as a predictive biomarker. This meta-analysis evaluates the evidence for baseline rsFC as a predictor of treatment outcomes of MDD interventions.
methodWe included MDD literature published between 2012 and 2024 that used antidepressants, non-invasive brain stimulation, and cognitive behavioral therapy. Pearson correlations or their equivalents were analyzed between baseline rsFC and treatment outcome. Nodes were categorized according to the type of brain networks they belong to, and pooled coefficients were generated for rsFC connections reported by more than three studies.
resultAmong the 16 included studies and 892 MDD patients, data from nine studies were used to generate pooled coefficients for the rsFC connection between the frontoparietal network (FPN) and default mode network (DMN), and within the DMN (six studies each, with three overlapping studies, involving 534 and 300 patients, respectively). The rsFC between the DMN and FPN had a pooled predictability of -0.060 (p = 0.171, fixed effect model), and the rsFC within the DMN had a pooled predictability of 0.207 (p < 0.001, fixed effect model). The rsFC between the DMN and FPN and the rsFC within the DMN had a larger effect in predicting the outcome of non-invasive brain stimulation (-0.215, p < 0.001, fixed effect model) and antidepressants (0.315, p < 0.001, fixed effect model), respectively. Heterogeneity was observed in both types of rsFC, study design, sample characteristics and data analysis pipeline.
conclusionBaseline rsFC within the DMN and between the DMN and FPN demonstrated a small but differential predictive effect on the outcome of antidepressants and non-invasive brain stimulation, respectively. The small predictability of rsFC suggested that rsFC between the FPN and DMN and the rsFC within the DMN might not be a good biomarker for predicting treatment outcome. Future research should focus on exploring treatment-specific predictions of baseline rsFC and its predictive utility for other types of MDD interventions.
trial registrationThe review was pre-registered at PROSPERO CRD42022370235 (33).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.